Early Postoperative Prevention and Treatment of Median Sternotomy Scars With Botulinum Toxin Type A Injection
Scar
About this trial
This is an interventional prevention trial for Scar focused on measuring Botulinum toxin type A, scar
Eligibility Criteria
Inclusion Criteria:
- Patients included are older than 18 years with a median sternotomy less than 14 days.
- Patients are willing and able to participate in the study as an outpatient, making several visits to the study center during the treatment and follow-up periods.
- Patients can comply with all study requirements including concomitant medication and other treatment restrictions.
- Patients have good wound healing condition, without infection sign.
Exclusion Criteria:
- The exclusion criteria applied is current pregnancy or breast feeding, allergy to botulinum toxin type A, previous injection of botulinum toxin within 6 months prior to enrollment, Myasthenia gravis or other neuromuscular disorder,and refusal to participate in this trial.
Sites / Locations
- Xijing Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Botulinum toxin type A
Normal Saline
The entire median sternotomy wound was divided into the upper half and the lower half. Both halves of the wound were randomized to receive treatment with either BTA or 0.9% normal saline.100U Botulinum toxin type A(BTA) will be reconstituted with 2mL of normal saline for a concentration of 50U/mL. 0.1ml(5 units) of BTA will be injected along the wound edges. The injections will be administered within 14 days of median sternotomy with a 30G needle.
The entire median sternotomy wound was divided into the upper half and the lower half. Both halves of the wound were randomized to receive treatment with either BTA or 0.9% normal saline.0.1ml normal saline will be injected along the wound edges.